ARTICLE | Finance
Out of the abyss: 3Q23 market preview
Biotech investors see the worst fading into the rearview mirror, point out indicators to watch for a recovery
July 15, 2023 12:47 AM UTC
With a robust rebound in the second quarter, the biotech sector is poised for a more constructive back half of 2023 as it charts a path to recovery.
Positive shifts in the capital markets are becoming evident, with buyside investors reporting an increase in pre-IPO meetings to test the waters and a perceived thawing of the market. This, coupled with a rise in M&A activity and follow-on offerings, indicates a more favorable environment for biotech companies...
BCIQ Company Profiles